UCLB spinout company, Orchard Therapeutics, a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene [...]
Valoctocogene Roxaparvovec Demonstrated Sustained Normal or Near Normal Factor VIII Levels in Severe Hemophilia A for Most Patients at Both Doses in Phase 1/2 S [...]
UCL spinout company, Puridify Limited, developers of bioprocessing technologies to significantly advance industrial biomolecule manufacture has been acquired by [...]
BioMarin today announced that the U.S. Food and Drug Administration (FDA) granted valoctocogene roxaparvovec (formally BMN 270) a Breakthrough Therapy Designati [...]
Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies to enable the development and manufacture of biopharm [...]
First four drug discovery programmes now launched in collaboration with academics at all three partner universities - spanning a variety of disease areas and dr [...]
Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies to enable the development and manufacture of biopharm [...]
Ocera Therapeutics, Inc. announces top-line results from its exploratory STOP-HE Phase 2b Study evaluating the efficacy, safety and tolerability of intravenousl [...]
Intract Pharma, an oral drug delivery spinout company from UCL School of Pharmacy and Finch Therapeutics, Inc., a microbiome therapeutics company based in Somer [...]
The UCL Technology Fund (UCLTF), which provides funding and support for UCL’s most transformative innovations, has approved an investment of up to £1m in Profes [...]
